Please assess the completion status of the following clinical trial:

Trial Title: FACBC Outcomes for Post Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the prostate, post radical-prostatectomy Detectable PSA~* ECOG/Zubrod Performance Status of 0-2~* Negative technetium 99-m MDP or F-18 PET bone scan for skeletal metastasis~* CT or MR scan of abdomen and pelvis which does not suggest presence of metastatic disease outside of the pelvis~* Willingness to undergo pelvic radiotherapy.~Exclusion Criteria:~* Contraindications to radiotherapy (including active inflammatory bowel disease or prior pelvic XRT)~* Inability to undergo anti-3-\[18F\]FACBC PET-CT~* Age under 18~* Metastatic disease outside of pelvis on any imaging or biopsy~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years~* Severe acute co-morbidity, defined as follows:~  * Unstable angina and/or congestive heart failure requiring hospitalization in the last 3 months~ * Transmural myocardial infarction within the last 6 months~ * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration~ * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration~ * Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immunocompromised patients

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- FACBC PET scan (Type: EXPERIMENTAL): A trial group in which anti-3-\[18F\]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
- Conventional-Only Imaging (Type: ACTIVE_COMPARATOR): A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.

Based on this trial design, predict the completion outcome and termination type (if applicable).